Acadia Pharmaceuticals (ACAD) Work In Process (2018 - 2026)

Acadia Pharmaceuticals' Work In Process history runs 9 years deep, the most recent figure standing at $80.7 million for Q1 2026.

• In Q1 2026, Work In Process rose 0.87% year-over-year to $80.7 million; the TTM figure through Mar 2026 stood at $80.7 million (up 0.87% YoY), while the FY2025 annual figure was $76.7 million, up 9.98% from the prior year.
• Work In Process for Q1 2026 stood at $80.7 million, up from $76.7 million in the prior quarter.
• The five-year high for Work In Process was $84.4 million in Q2 2025, with the low at $4.6 million in Q3 2023.
• The 5-year median for Work In Process is $6.2 million (2022), against an average of $32.8 million.
• The sharpest annual moves came in 2023 and 2024: Work In Process dropped 22.76% in 2023, then surged 1406.94% in 2024.
• Acadia Pharmaceuticals' Work In Process stood at $4.9 million in 2022, then slipped by 6.01% to $4.6 million in 2023, then soared by 1406.94% to $69.7 million in 2024, then gained by 9.98% to $76.7 million in 2025, then grew by 5.23% to $80.7 million in 2026.
• Business Quant data shows ACAD's Work In Process at $80.7 million in Q1 2026, $76.7 million in Q4 2025, and $76.9 million in Q3 2025.